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An essential function of innate immunity is 
initiating inflammatory responses to limit 
the spread of invading pathogens, followed 
by regulatory mechanisms aimed at resolv-
ing inflammation and returning the immune 
system to homeostasis. These meticulously 
regulated processes are triggered by various 
pathogen-associated molecular patterns or 
endogenous damage-associated molecu-
lar patterns. A group of natural peptides 
that have gained notoriety in recent years 
as immune-modulatory molecules con-
tributing to both resolution of infections 
and inflammation, thus playing a role in 
maintaining homeostasis are host defense 
peptides (HDPs). These are gene-encoded 
cationic short peptides, less than 50 amino 
acids with an overall positive charge of +2 
to +7, and ≥30% of hydrophobic residues. 
The two most well characterized families 
of HDPs in mammals are cathelicidins and 
defensins. We will focus on cathelicidin 
HDPs in this review.
Genes encoding cathelicidin HDPs 
have a highly conserved N-terminal cathe-
lin domain in their precursor protein 
(Tomasinsig and Zanetti, 2005). This con-
served cathelin domain has helped in the 
discovery of new cathelicidins from diverse 
species including non-mammalian species 
such as chicken, trout, and hagfish. The bio-
logical active mature mammalian catheli-
cidin peptides are processed from their 
precursor protein by proteolytic cleavage by 
serine proteases, e.g., proteinase 3, elastase, 
and kallikrein (Shinnar et al., 2003; Morizane 
et al., 2010). The biologically active mature 
cathelicidins are diverse in their sequence 
and structure, and can be classified into four 
structural groups; amphipathic α-helices 
(e.g., murine CRAMP), β-hairpin mol-
ecules (e.g., porcine protegrin 1), those with 
extended structures (e.g., bovine indolici-
din), and cyclic peptides (e.g., bactenecin). 
Mammalian cathelicidins are found in gran-
ules of neutrophils as well as other cell types 
such as myeloid precursors, epithelial cells, 
mast cells, lymphocytes, and  keratinocytes. 
These peptides are expressed in a wide vari-
ety of tissues (oral cavity, skin, intestine, 
lungs, cervix, etc.) and found in body fluids 
such as plasma, breast milk, saliva, gastric 
juice, semen, sweat, and bronchoalveolar 
fluid (Nijnik and Hancock, 2009). The 
biologically active mature cathelicidin pep-
tides have been demonstrated to mediate a 
wide range of activity from antimicrobial 
to immune-modulatory (discussed below). 
Some of the most well studied cathelicidins 
are human LL-37, murine CRAMP, bovine 
BMAP-28, and porcine PR-39.
Protection against infections
Decreased expression of cathelicidin HDPs 
has been associated with increased suscepti-
bility to infections. For example, decreased 
expression of human cathelicidin LL-37 is 
linked to increased susceptibility to skin 
infections,  frequent oral bacterial infec-
tions, severe periodontal disease, and cuta-
neous infections by the parasitic protozoan 
leishmania (Bowdish et al., 2005; Kulkarni 
et al., 2011). A recent study has demon-
strated that the active metabolite of vita-
min D induces the expression of LL-37 thus 
contributing to protection against tuber-
culosis (Jo, 2010). Similarly, the murine 
cathelicidin CRAMP is known to provide 
protection against streptococcus infections 
(Nizet et al., 2001). Thus, it is not surprising 
that research in this area was propelled by 
the interest of developing these peptides as 
alternate antibiotic-like therapy for infec-
tious disease. However, it has been shown 
that the direct microbicidal activity of these 
peptides is often antagonized in the pres-
ence of physiological salt concentration, 
heparin, and serum factors (Bowdish et al., 
2005). Also, microbial factors such as poly-
saccharides released by certain pulmonary 
bacterial pathogens antagonize the direct 
microbial killing property of these pep-
tides (Benincasa et al., 2009). However, the 
fact remains that cathelicidins can indeed 
protect against a wide range of infections 
from bacteria, viruses, and parasites. As 
 cathelicidins have been also demonstrated to 
stimulate both innate and adaptive immune 
responses (discussed below), the ability of 
cathelicidins to contribute to resolution of 
infections is now thought to be primarily 
due to their role in host immunity.
role in immune-mediated 
inflammatory disorders
Altered expressions of cathelicidins have 
also been reported in auto-inflammatory 
or auto-immune diseases. Human LL-37 
is found to be suppressed in atopic der-
matitis and Crohn’s disease (Ong et al., 
2002; Wehkamp et al., 2007), but shown 
to be elevated in systemic lupus erythe-
matosus (SLE) and rheumatoid arthritis 
(Paulsen et al., 2002; Sun et al., 2011). It 
has been proposed that LL-37 can com-
plex with self DNA activating dendritic 
cells to contribute to the pathogenesis of 
SLE (Lande et al., 2011). Whereas, in pso-
riasis it has been hypothesized that LL-37 
can act both as an effector and a regulator 
(Kanda et al., 2010). Furthermore, a recent 
study has shown that LL-37 can interfere 
in the activation of inflammasome con-
tributing to suppression of pro-inflamma-
tory responses in psoriasis (Dombrowski 
et al., 2011). Consistent with this, it has 
been hypothesized that LL-37 can protect 
against auto-immune diseases, which may 
be in part mediated by vitamin D (Bartley, 
2010). Even though studies have demon-
strated that altered cathelicidin expression 
is associated with chronic inflammatory 
auto-immune diseases, clarification of their 
specific roles in immune-mediated inflam-
mation will require further investigations. 
Research in the last decade has established 
that cathelicidins mediate a wide range of 
immune functions including promotion 
of barrier repairs, chemokine and cytokine 
production, modulation of dendritic cell 
differentiation, and T-cell polarization, as 
well as demonstrate potent anti-sepsis and 
anti-inflammatory properties (discussed 
below). Elucidating the differential effects 
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Th1-responses (Nijnik et al., 2009). Another 
mechanism of inflammatory control dem-
onstrated for cathelicidin peptides, e.g., 
PR-39, is by proteosome-mediated degra-
dation of IκBα and subsequent inhibition 
of activation of NF-κB (Bao et al., 2001).
Intracellular uptake has been shown 
to be important for immunomodulatory 
activity of cathelicidins (Lau et al., 2005). 
This is mediated either by putative surface 
receptors (De et al., 2000; Lau et al., 2005) 
or by atypical endocytic pathways followed 
by interaction with intracellular receptor, 
e.g., GAPDH (Mookherjee et al., 2009). 
Specific receptor interaction for cathelicidin 
peptides and how this influences different 
immune-modulatory functions is yet to be 
completely resolved. The molecular mecha-
nism of the anti-inflammatory activity of 
cathelicidins appears to be very complex, 
requires intracellular uptake, interaction 
with either putative surface or intracellu-
lar receptors, leading to the alteration of 
various signaling pathways (e.g., NF-κB, 
p38 and JNK MAPK, PI3K) with different 
kinetics.
The overall result of immunomodu-
latory functions of cathelicidin HDPs is 
the net balancing or control of inflam-
mation without compromising immune 
responses that are required for resolution 
of infections. This duality or pro- and anti-
inflammatory biological activities of these 
peptides has made them attractive agents 
to be explored as therapeutics. The distinct 
advantages of developing cathelicidins 
and their derivatives as therapeutics are (i) 
the ability to control inflammation with-
out compromising the immune functions 
required to clear infections, and (ii) the 
unlikelihood of developing microbial resist-
ances against these peptides, since most of 
these peptides influence the immune system 
under physiological conditions to control 
infections rather than direct microbicidal 
activity (Afacan et al., 2012).
summary
Cathelicidins have been defined to play 
multiple roles in immunity contributing to 
both resolution of infections and inflamma-
tion. The molecular mechanisms govern-
ing the multiple functions of these peptides 
in immunity is very complex, involving 
various signaling pathways and multiple 
  transcription factors, and is influenced by 
response (Davidson et al., 2004). Apart 
from influencing the initiation of the 
adaptive immune response, recent studies 
have shown that cathelicidins also have a 
direct impact on lymphocytes. For exam-
ple, murine CRAMP can directly alter T- 
and B-cell responses, promote and regulate 
humoral and cellular antigen-specific adap-
tive immune responses (Kurosaka et al., 
2005; Kin et al., 2011). Overall, cathelicidins 
have a direct effect on immune cells influ-
encing both innate and adaptive immunity 
against pathogenic attack. Most of the above 
mentioned immunity-related activity medi-
ated by cathelicidins can be described as 
pro-inflammatory functions required for 
resolution of infections. However, these 
peptides also exhibit anti-inflammatory 
properties, thus playing a significant role 
in balancing inflammation and maintaining 
homeostasis.
control of inflammation by 
cathelicidins
Peptides such as LL-37 and CRAMP have 
been demonstrated to confer protection in 
animal models of pathogenic sepsis (Cirioni 
et al., 2006), and have anti-inflammatory 
effects in “sterile” inflammatory diseases 
such as ulcerative colitis (Wong et al., 
2012). Consistent with this, cathelicidin 
knock out mice show increased inflam-
matory responses compared to wild type 
(Morioka et al., 2008). Recent studies have 
also shown that synthetic cationic peptides 
derived from cathelicidins can indeed sup-
press inflammation in infection models 
(Scott et al., 2007) and in immune-mediated 
inflammatory models (Turner-Brannen 
et al., 2011).
Mechanistic studies have demonstrated 
that cathelicidins intervene at multiple 
points within the inflammatory cascade to 
suppress inflammation in a targeted fashion. 
For example, human and bovine cathelici-
dins alter the TLR-to-NF-κB pathway in the 
presence of exogenous inflammatory stimuli 
(e.g., endotoxin) and selectively suppress 
specific pro-inflammatory cellular responses 
such as TNF-α, TNFAIP2, IL-1β, and 
NFκB1 (Mookherjee et al., 2006). In con-
trast, anti-inflammatory mediators such as 
IL-10, TNFAIP3, NF-κB inhibitor NFκBIA 
are enhanced by these peptides (Mookherjee 
et al., 2006; Brown et al., 2011). It has also 
been shown that LL-37 can inhibit cellu-
lar immune responses   triggered by IFN-γ, 
of pro- and anti-inflammatory functions 
mediated by these peptides resulting in 
both immune activation and control of 
inflammation represents an exciting area 
of research.
cathelicidin-mediated immune 
activation
A primary innate immune function medi-
ated by cathelicidins is the facilitation of 
immune cell recruitment, either by direct 
chemoattractant properties or indirectly 
by inducing the production of chemokines. 
For example, human LL-37 and porcine 
PR-39 are direct chemoattractants for 
neutrophils, monocytes, T-cells, mast cells, 
etc. (Yang et al., 2001; Niyonsaba et al., 
2002; Tjabringa et al., 2006). In addition, 
cathelicidins such as LL-37 can also pro-
mote chemotaxis by inducing the produc-
tion of chemokines, e.g., MCP-1, RANTES, 
Gro-α, and IL-8 from both immune cells 
and other cell types such as epithelial 
cells and gingival fibroblasts (Mookherjee 
et al., 2006; Montreekachon et al., 2011). 
LL-37 also up-regulates the expression 
of chemokine receptors such as CXCR4, 
CCR2, and IL-8RB in macrophages (Scott 
et al., 2002). Mediating recruitment of leu-
kocytes and thus aiding in phagocytosis to 
enhance clearance of pathogens is one of the 
critical innate immune functions of catheli-
cidin peptides. Furthermore, cathelicidins 
such as LL-37 synergistically enhances anti-
infective immune responses in the presence 
of certain critical cytokines such as IL-1β 
and GM-CSF (Yu et al., 2007). Other innate 
immune activating properties of cathelici-
dins are (i) mediating protection against 
mycobacterium by promoting autophagy 
in macrophages (Yuk et al., 2009), (ii) 
prolonging the life span of neutrophils by 
inducing the expression of anti-apoptotic 
protein BcL-XL and inhibiting caspase-3 
activity, thus enhancing phagocytosis by 
neutrophils (Nagaoka et al., 2006), and 
(iii) enhancing epithelial wound healing 
(Carretero et al., 2008).
Cathelicidins such as human LL-37 
appear to be a link between the innate and 
adaptive immune responses by influencing 
dendritic cell activiation and polarization 
of T-lymphocytes (Davidson et al., 2004; 
Bandholtz et al., 2006). LL-37 up-regulates 
the endocytic capacity of dendritic cells and 
enhances the secretion of cytokines that 
aid in the polarization of a Th1 immune 
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signals. Moreover, the process of endocytic 
uptake or interaction with specific receptors 
and how this mediates the diverse immu-
nomodulatory functions of cathelicidins is 
not completely understood. However, evi-
dence in the last decade revealing the duality 
of pro- and anti-inflammatory functions of 
cathelicidins, resulting in the promotion of 
immune responses required for resolution 
of infections and at the same time control-
ling inflammation, has captured the inter-
est of biomedical researchers. Consequently, 
there has been a keen interest in the devel-
opment of these peptides, in particular their 
synthetic derivatives as therapeutics; as 
antimicrobials, anti-inflammatory agents, 
adjuvants, and in wound healing. The 
challenges however are limited pharma-
cokinetic or toxicology data, bioavailability, 
and high manufacturing costs. Establishing 
the immune-regulatory properties of HDPs 
such as cathelicidins and exploring their 
potential as immunomodulatory thera-
peutics represents an exciting avenue of 
research that is growing rapidly.
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